Known allergies, hypersensitivity, or intolerance to any of the study medications, excipients, or similar compounds.
Patients must have no known allergies to exemestane, entinostat, or medications that have a benzamide structure (e.g., tiapride, remoxipride, clebropride)
Patients with known and documented allergies to any of the penicillins, cephalosporins, or beta-lactamase inhibitors
Subjects with known allergies, hypersensitivity, or intolerance to niraparib or its excipients
Known allergies to medical adhesives or hydrogel
Known allergies to medical adhesives or hydrogel
History of allergies to any active or inactive ingredients of atezolizumab.
Participants with known allergies, hypersensitivity, or intolerance to ibrutinib or its excipients (refer to Investigator's Brochure)
Patients with known or suspected allergies to any component of the vaccine.
Known allergies to medical adhesives or hydrogel
Patients with known contrast allergies requiring pre-medication with steroids
Known allergies, hypersensitivity or intolerance to apalutamide, abiraterone acetate, prednisone, or GNRH agonist or GNRH antagonist
Known allergies, hypersensitivity, or intolerance to erdafitinib or its excipients
Subjects with three or more drug allergies from separate drug classes
Known allergies, hypersensitivity, or intolerance to any of the study medications, excipients, or similar compounds
History of multiple drug allergies or intolerance to subcutaneous injections
Subjects with three or more drug allergies from separate drug classes
Allergies, hypersensitivity, or intolerance to prednisone, LHRH analog or excipients of prednisone LHRH analog, abiraterone acetate and apalutamide.
Known allergies, hypersensitivity, or intolerance to any of the study medications, excipients, or similar compounds
Subject has known severe allergies, hypersensitivity, or intolerance to monoclonal antibodies or human proteins, or their excipients (refer to the latest version of the Investigator Brochure), or known sensitivity to mammalian-derived products
Known allergies, hypersensitivity, or intolerance to corticosteroids, monoclonal antibodies or human proteins, or their excipients (refer to respective package inserts or investigator's brochure), or known sensitivity to mammalian-derived products
Allergies to any vaccine, that after discussion with Immunovaccine, are serious enough to warrant exclusion from this study
Have known allergies, hypersensitivity, or intolerance to ARN- (apalutamide) or its excipients
Prior use of niclosamide or allergies to niclosamide
Allergies to Lidocaine or Novocain
Allergies to imaging dyes
Documented penicillin or cephalosporin allergies
Subjects with any underlying conditions, which would contraindicate therapy with, study treatment (or allergies to reagents used in this study)
Known allergies to any of the components of the investigational treatment regimen or required ancillary treatments
Patients with allergies to any component of the vaccine will be excluded from the protocol
Subjects must not have allergies to any compounds similar to CDB-
Have known allergies, hypersensitivity, or intolerance to abiraterone acetate, apalutamide or prednisone or their excipients
Known allergies, hypersensitivity, or intolerance to the IP or its excipients
Allergies, hypersensitivity, or intolerance to niraparib or the corresponding excipients
Allergies to lidocaine or marcaine
Allergies to imaging dyes
Known history of allergies or sensitivities to gentamicin.
Patients with allergies to isosulfan blue or technetium, which would preclude sentinel node mapping
Subject has known allergies, hypersensitivity, or intolerance to monoclonal antibodies or human proteins, or their excipients
Antibiotic allergies that would preclude treatment for a C. novyi-NT infection
Subject has known allergies, hypersensitivity, or intolerance to boron or mannitol, corticosteroids, monoclonal antibodies or human proteins, or their excipients (refer to respective package inserts or Investigator's Brochure), or known sensitivity to mammalian-derived products
Participants with known or suspected allergies to any component of the vaccine
Known allergies to clofarabine, melphalan, sirolimus or tacrolimus
Known allergies, hypersensitivity, or intolerance to any of the study medications, excipients, or similar compounds.
Known allergies, hypersensitivity, or intolerance to Doxil, dexamethasone, or their excipients
Known allergies, hypersensitivity, or intolerance to talacotuzumab and daratumumab or their excipients
Allergies or hypersensitivities to monoclonal antibodies, BMS- or related compounds, including fucosyl-GM vaccine and Nivolumab
Subjects with any known severe allergies (e.g. anaphylaxis) to any active or inactive ingredients in the study drugs.
Participant has known allergies, hypersensitivity, or intolerance to imetelstat or its excipients
Known allergies, hypersensitivity, or intolerance to any form of heparin or azacitidine
No eating disorders, food allergies or intolerances
Have known allergies, hypersensitivity, or intolerance to AA or prednisone or their excipients
Have known allergies, hypersensitivity, or intolerance to abiraterone acetate or prednisone or their excipients
Have known allergies, hypersensitivity, or intolerance to enzalutamide or their excipients
Have known allergies, hypersensitivity, or intolerance to abiraterone acetate or prednisone or their excipients
Any prior allergies to curcumin or turmeric
Known allergies to any of the components of the investigational treatment regimen or required ancillary treatments
Any history of allergies to grapes or grape seed
Have known allergies, hypersensitivity, or intolerance to abiraterone acetate or prednisone or their excipients
Known allergies, hypersensitivity or intolerance to abiraterone acetate, prednisone or degarelix
Subjects with any underlying conditions which would contraindicate therapy with study treatment (or allergies to reagents)
Subject has any underlying conditions, which would contraindicate therapy with study treatment (or allergies to reagents used in this study)
Known allergies, hypersensitivity, or intolerance to TRC or its excipients.
Have known allergies, hypersensitivity, or intolerance to docetaxel or dexamethasone or their excipients
Antibiotic allergies that would preclude treatment for a C. novyi-NT infection.
Allergies to excipients in the study drug.
Hypersensitivities, allergies or contraindications to study medications; intolerance of medical tape or sticking plaster.
Have known allergies, hypersensitivity, or intolerance to enzalutamide or niclosamide or their excipients
Known allergies, hypersensitivity or intolerance to prednisone or excipients of abiraterone acetate or enzalutamide. History of hypersensitivity to docetaxel or polysorbate .
Have known allergies or hypersensitivity to abiraterone acetate or prednisone or their excipients
Allergies to temozolomide, dacarbazine, IgG containing agents
Patients with known allergies, hypersensitivity, or intolerance to abiraterone acetate or prednisone or their excipients
Allergies to any component of the vaccine
Known unmanageable allergies, hypersensitivity, intolerance to monoclonal antibodies, to murine, chimeric, human proteins or their excipients
Known allergies, hypersensitivity, or intolerance to trabectedin, dacarbazine, dexamethasone, or their excipients
Known allergies, hypersensitivity, or intolerance to dacarbazine does not apply
Allergies to eggs, lecithin or soy products.
No allergies to and not currently using varenicline
Subjects with allergies to any supplements.
Patients with allergies to any of the ingredients in the nutritional supplement
Known allergies or intolerance to cisplatin and similar platinum-containing compounds
Allergic history, including anaphylaxis or severe allergies to products in study serum or placebo
Hypersensitivity to any tetracycline, or a history of other allergies or drug reactions that in the treating physician's judgment make the patient inappropriate for this study
Has known allergies or intolerance to brilacidin, cisplatin or carboplatin
Patients will be excluded from the trial if they have had a history of allergies or intolerance to fructooligosaccharides or the components of FOS including fructose and glucose
Known allergies or intolerance to cisplatin and similar platinum-containing compounds
Known allergies, hypersensitivity, or intolerance to any of the study medications.
All patients who are have known allergies or are sensitive to silver and acrylic adhesives
Allergies to multiple food items or nutritional supplements
Known allergies, hypersensitivity, or intolerance to corticosteroids, monoclonal antibodies, hyaluronidase, or other human proteins, or their excipients, or known sensitivity to mammalian-derived products
History of food allergies and/or major dietary restrictions
Subjects should not have known allergies to cruciferous vegetables
No known allergies to tree nuts (i.e. almonds)
Subjects with three or more drug allergies from separate drug classes
Subject has known allergies, hypersensitivity, or intolerance to monoclonal antibodies or human proteins, or their excipients (refer to respective package inserts or investigator's brochure)
Subjects with three or more drug allergies from separate drug classes
No known allergies to contrast material
No known allergies to contrast material
Known allergies to contrast material
History of allergies to iodides
Subjects with a history of iodide allergies
Subjects with three or more drug allergies from separate drug classes
Subjects with three or more drug allergies from separate drug classes
Allergies to study medications, such as, lidocaine, Versed, or Cetacaine
Allergies and Adverse Drug Reaction a. Subjects with known hypersensitivity to excipients of Dasatinib tablets
